Tousignant Jennifer sold 4,212 shares of Viridian Therapeutics, Inc. DE at $24.50 for −$103k on Aug 19, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Legal Officer
Chief Legal Officer
Filed Aug 20, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$103,194Shares × reported price
Shares traded
4,212Common Stock
Price per share
$24.50Reported price. Read footnotes for ranges.
% of reported position traded
100%This security and ownership context
Holdings after
0Direct
Trade date
Aug 19, 2026Sell
Filed
Aug 20, 2026, 8:05 PM ET2-day reporting delay
Accession
0001193125-26-359636Code S · Transaction 15421
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 4,212 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 19, 2026Option exercise10,000$14.41$144,100Trade 15422
Aug 19, 2026Option exercise10,000$0.00$0Trade 15424
Aug 19, 2026Sell10,000$24.50−$245,000Trade 15423
4 transaction rows in this filing. Joint filers share the same rows.

VRDN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
VRDN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −24%1w ago −5.8%1d ago −1.5%
Returns since7d −5%30d −5.2%90d180d1y

Footnotes in full

F1: The shares sold include 718 shares previously acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c). F2: The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.